Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572

AIMS: S/GSK1349572 is an unboosted, once daily, next generation integrase inhibitor with potent activity, low pharmacokinetic (PK) variability and a novel resistance profile. As the primary route of metabolism is via glucuronidation, the effects of atazanavir (ATV, a UGT1A1 inhibitor) and atazanavir...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Song, Ivy, Borland, Julie, Chen, Shuguang, Lou, Yu, Peppercorn, Amanda, Wajima, Toshihiro, Min, Sherene, Piscitelli, Stephen C
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Science Inc 2011
Pynciau:
Drug Interactions
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3141191/
https://ncbi.nlm.nih.gov/pubmed/21342217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.03947.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg